辉瑞的实验性月度减重药物在试验中显示减重率可达12.3%，副作用轻微且无停滞期，但因停药率高达10%，份额有所下降。 Pfizer's experimental monthly weight-loss drug showed up to 12.3% weight loss in trials, with mild side effects and no plateau, but shares dropped due to a 10% discontinuation rate.

根据2026年2月3日公布的数据,辉瑞的GLP-1实验月度药物PF-3944在28周的中阶段试验中,体重减幅达到12.3%,没有结果,一般是轻微副作用。 Pfizer's experimental monthly GLP-1 drug, PF-3944, achieved up to 12.3% weight loss over 28 weeks in a mid-stage trial, with no plateau in results and generally mild side effects, according to data released on February 3, 2026. 这一药物是通过购买Metsera100亿美元获得的,是辉瑞推动1 500亿美元肥胖症市场的一部分,计划在2026年进行10个阶段3试验,并可能在2028年得到批准。 The drug, acquired through a $10 billion purchase of Metsera, is part of Pfizer’s push into the $150 billion obesity market, with plans for 10 Phase 3 trials in 2026 and potential approval by 2028. 尽管第四季度收入强劲,销售额强劲,但辉瑞公司的份额下降了3.5%,因为人们担心由于副作用导致10%的停产率,尽管没有关于严重肠胃事件的报告。 Despite strong fourth-quarter earnings and robust sales, Pfizer’s shares fell 3.5% amid concerns over a 10% discontinuation rate due to side effects, though no severe gastrointestinal events were reported. 尽管专利到期和价格压力,该公司重申其2026年的收入预测。 The company reaffirmed its 2026 revenue forecast despite patent expirations and pricing pressures.